Aaron H. (2003) The costs of health care administration in the United States and Canada—questionable answers to a questionable question. New England Journal of Medicine 349(8): 801–803CrossRef
Adam M. (2008) Promoting disinterestedness or making use of bias? Interests and moral obligation in commercialized research. In: Carrier M., Howard D., Kourany J. (eds) The challenge of the social and the pressure of practice: Science and values revisited. Pittsburgh University Press, Pittsburgh, PA, pp 235–255
Als-Nielsen B., Chen W., Gluud C., Kjaergard L. (2003) Association of funding and conclusion in randomized drug trials: A reflection of treatment effect of adverse events?. Journal of the American Medical Association 290(7): 921–928CrossRef
Angell M. (2004) The truth about the drug companies. Random House, New York, NY
Anuradha, R. V. (2001, May 20). Biopiracy and traditional knowledge. The Hindu.
Bekelman J., Li Y., Gross C. (2003) Scope and impact of financial conflicts of interest in biomedical research. Journal of the American Medical Association 289(4): 454–465CrossRef
Biddle J. (2007) Lessons from the Vioxx debacle: What the privatization of science can teach us about social epistemology. Social Epistemology 21: 21–39CrossRef
Blumenthal D., Campbell E., Anderson M., Causino N., Louis K. (1997) Withholding research results in academic life science. Journal of the American Medical Association 277(15): 1224–1228CrossRef
Bodenheimer T. (2000) Uneasy alliance. New England Journal of Medicine 342(20): 1539–1544CrossRef
Boldrin, M., & Levine, D. (2002). Perfectly competitive innovation. Research Department Staff Report 303. Minneapolis, MN.
Boldrin M., Levine D. (2008) Against intellectual monopoly. Cambridge University Press, CambridgeCrossRef
Brown J. R. (2002) Funding, objectivity and the socialization of medical research. Science and Engineering Ethics 8: 295–308CrossRef
Brown J. R. (2004) Money, method, and medical research. Episteme 1: 49–59CrossRef
Brown, J. R. (2006). Regulation and research: Approaches to market failures in medicine. In Commerce, politics and science conference, Notre Dame.
Brown J. R. (2008) The community of science®. In: Carrier M., Howard D., Kourany J. (eds) The challenge of the social and the pressure of practice: Science and values revisited. Pittsburgh University Press, Pittsburgh, PA, pp 189–216
Campbell E., Gruen R., Mountford J., Miller L., Cleary P., Blumenthal D. (2007) A national survey of physician-industry relationships. New England Journal of Medicine 356(17): 1742–1750CrossRef
Carrier M. (2008) Science in the grip of the economy: On the epistemic impact of the commercialization of research. In: Carrier M., Kourany J., Howard D. (eds) The challenge of the social and the pressure of practice: Science and values revisited. University of Pittsburgh Press, Pittsburgh, PA, pp 217–234
Cartwright N. (2006) Well-ordered science: Evidence for use. Philosophy of Science 73: 981–990CrossRef
Cartwright N. (2007) Are RCTs the gold standard?. BioSocieties 2(2): 11–20CrossRef
Chalmers I. (1990) Underreporting research is scientific misconduct. Journal of the American Medical Association 263(10): 1405–1408CrossRef
Chin, T. (2002, May 6). Drug firms score by paying doctors for time. American Medical News.
Chow S.-C., Liu J.-P. (2002) Design and analysis of clinical trials: Concepts and methodologies (2nd ed.). Wiley, Hoboken, NJ
Christensen J., Orlowski J. (2005) Bounty-hunting and finder’s fees. IRB: Ethics & Human Research 27(3): 16–19CrossRef
Cohen J., Gürtler R. (2001) Modeling household transmission of American trypanosomiasis. Science 293: 694–698CrossRef
De Francisco, A., & Matlin, S. (2006). Monitoring financial flows for health research 2006: The changing landscape of health research for development. Geneva: Global Forum for Health Research.
Donohue J., Cevasco M., Rosenthal N. (2007) A decade of direct-to-consumer advertising of prescription drugs. New England Journal of Medicine 357: 673–681CrossRef
Getz K. (1999) AMCs rekindling clinical research partnerships with industry. Centerwatch, Boston
Global Forum for Health Research. (2004a). The 10/90 report on health research 2003–2004. Geneva: Global Forum for Health Research.
Global Forum for Health Research. (2004b). Monitoring financial flows for health research (Vol. 2). Geneva: Global Forum for Health Research.
Harris, G. (2004, December 6). At F.D.A., strong drug ties and less monitoring. New York Times.
Hartman, M., Martin, A., McDonnell, P., Catlin, A., & the National Health Expenditure Accounts Team. (2009). National health spending in 2007: Slower drug spending contributes to lowest rate of overall growth since 1998. Health Affairs, 28(1), 246–261.
Heffner, S. (2004, March). Beyond the CRO. Contract Pharma.
Hilts P. (2003) Protecting America’s health: The FDA, business, and one hundred years of regulation. University of North Carolina Press, Chapel Hill, NC.
Hollis A., Pogge T. (2008) The health impact fund: Making new medicines accessible for all. New Haven, CT, Incentives for Global Health
Howson C., Urbach P. (2005) Scientific reasoning: The Bayesian approach. Open Court, Chicago and LaSalle, IL
Kaiser Family Foundation. (2008). Prescription drug trends. Menlo Park, CA: Kaiser Family Foundation.
Kincaid H. (2004) Contextualism, explanation and the social sciences. Philosophical Explorations 7(3): 201–218CrossRef
Kincaid, H., Dupré, J., Wylie, A. (eds) (2007) Value-free science? Ideals and illusions. Cambridge University Press, Cambridge
Kincaid, H., McKitrick, J. (eds) (2007) Establishing medical reality: Essays on the metaphysics and epistemology of science. Springer, Heidelberg
Kitcher P. (1993) The advancement of science. Oxford University Press, Oxford
Kitcher P. (2001) Science, truth and democracy. OUP, OxfordCrossRef
Kreling, D., Mott, D., Wiederholt, J., Lundy, J., & Levitt, L. (2001). Prescription drug trends: A chartbook update. Menlo Park, CA: Kaiser Family Foundation.
Krimsky S. (2003) Science in the private interest: Has the lure of profits corrupted biomedical research?. Rowman & Littlefield, Lanham, MD
Longino H. (1990) Science as social knowledge. Princeton Universty Press, Princeton, PA
Longino H. (2002) The fate of knowledge. Princeton Universty Press, Princeton, PA
Mayo D. (1996) Error and the growth of experimental knowledge. University Press, Chicago IL
McGoey, L., Reiss, J., & Wahlberg, A. (forthcoming). The health complex: Progress and pathologies in global health funding and governance. BioSocieties.
Mirowski P., Sent E.-M. (2002) Introduction, Science bought and sold: Essays in the economics of science. University of Chicago Press, Chicago IL
Mirowski P., Van Horn R. (2005) The contract research organization and the commercialization of scientific research. Social Studies of Science 34(4): 503–548CrossRef
Mitchell S. (2009) Unsimple truths. University of Chicago Press, Chicago, IL
Morgan S., Raymond C., Mooney D., Martin D. (2008) The Canadian RX atlas (2nd ed.). Centre for Health Services and Policy Research, Vancouver, BC
Moynihan R. (2003) Who pays for the pizza? Redefining the relationships between doctors and drug companies. British Medical Journal 326: 1189–1196CrossRef
Pogge T. (2005) Human rights and global health: A research program. Metaphilosophy 36(1/2): 182–209CrossRef
Pollack, A. (2001, January 8). Bristol-Myers and Athersys make deal on gene patents. New York Times.
Public Citizen. (2001). Rx R&D myths: The case against the drug industry’s R&D “scare card”. Washington, DC: Public Citizen.
Public Citizen. (2003). 2002 Drug industry profits: Hefty pharmaceutical company margins dwarf other industries. Washington, DC: Public Citizen.
Public Library of Science. (2006). Special issue on disease mongering. PLoS Medicine, 3(4).
Putnam H. (2002) The fact/value dichotomy and other essays. Harvard University Press, Cambridge, MA
Reiss J., Kitcher P. (2009) Biomedical research, neglected diseases and well-ordered science. Theoria 24(3): 263–282
Risse, M. (forthcoming). The grounds of justice. Princeton, NJ: Princeton University Press.
Rosenthal M., Bernt E., Donohue J., Frank R., Epstein A. (2002) Promotion of prescription drugs to consumers. New England Journal of Medicine 346(7): 498–505CrossRef
Selgelid M. (2005) Ethics and infectious disease. Bioethics 19(3): 272–289CrossRef
Shuchman M. (2007) Commercializing clinical trials—risks and benefits of the CRO boom. New England Journal of Medicine 357(14): 1365–1368CrossRef
Stiglitz J. (2006a) Making globalization work. Norton, New York, NY
Stiglitz J. (2006b) Scrooge and intellectual property rights: A medical prize fund could improve the financing of drug innovations. British Medical Journal 333: 1279–1280CrossRef
Wilholt T. (2006) Design rules: Industrial research and epistemic merit. Philosophy of Science 73(1): 66–89CrossRef
Wilkes M., Bell R., Kravitz R. (2000) Direct-to-consumer prescription durg advertising: Trends, impact, and implications. Health Affairs 19(2): 110–128CrossRef
Woolhandler S., Campbell T., Himmelstein D. (2003) Costs of health care administration in the United States and Canada. New England Journal of Medicine 349: 768–775CrossRef
Worrall J. (2002) What evidence in evidence-based medicine. Philosophy of Science 69: S316–S330CrossRef